The Mighty Multipurpose Statins

3262

By: W. Langbein

Cholesterol-lowering statins significantly lower the increased concentrations of coagulation and inflammation markers, both cardiovascular disease risk factors common in type 2 diabetes.

According to a randomized 50-patient study in the Netherlands, after eight weeks of treatment with pravastatin (marketed in the United States as Pravachol), researchers observed significant reductions in three plasma coagulation and inflammation markers, as well as a 13 percent reduction in C-reactive protein, an indicator of inflammation.

The researchers speculate that the anti-thrombotic and anti-inflammatory effects of statin treatment could play a role in reducing the cardiovascular complications associated with type 2 diabetes.

-Diabetes Care, February 2004

Clinical adviser’s note: For more information on the class of lipid-regulating drugs called HMG-CoA reductase inhibitors (“statins” for short), please refer to our January 2004 Product Reference Guide issue, pp. 38-44.

Comments

comments

Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.